KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Gains from Sales and Divestitures (2016 - 2017)

Historic Gains from Sales and Divestitures for Idexx Laboratories (IDXX) over the last 6 years, with Q4 2017 value amounting to $155000.0.

  • Idexx Laboratories' Gains from Sales and Divestitures fell 882.35% to $155000.0 in Q4 2017 from the same period last year, while for Dec 2017 it was $155000.0, marking a year-over-year decrease of 882.35%. This contributed to the annual value of $155000.0 for FY2017, which is 882.35% down from last year.
  • Latest data reveals that Idexx Laboratories reported Gains from Sales and Divestitures of $155000.0 as of Q4 2017, which was down 882.35% from $170000.0 recorded in Q4 2016.
  • In the past 5 years, Idexx Laboratories' Gains from Sales and Divestitures ranged from a high of $170000.0 in Q4 2016 and a low of $122000.0 during Q4 2014
  • In the last 4 years, Idexx Laboratories' Gains from Sales and Divestitures had a median value of $147000.0 in 2013 and averaged $146500.0.
  • Per our database at Business Quant, Idexx Laboratories' Gains from Sales and Divestitures tumbled by 794.7% in 2013 and then plummeted by 1223.02% in 2014.
  • Quarter analysis of 4 years shows Idexx Laboratories' Gains from Sales and Divestitures stood at $139000.0 in 2013, then decreased by 12.23% to $122000.0 in 2014, then skyrocketed by 39.34% to $170000.0 in 2016, then fell by 8.82% to $155000.0 in 2017.
  • Its Gains from Sales and Divestitures was $155000.0 in Q4 2017, compared to $170000.0 in Q4 2016 and $122000.0 in Q4 2014.